



Using behavioural science to improve antibiotic stewardship in Canadian long-term care homes: Protocol for a multi-center cluster randomized quality improvement study

Tyler Good^{1*}, Jorida Cila¹, Rhiannon Mosher¹, Klajdi Puka^{1,2}, Shaghig Reynolds³, Barbara Catt³, Aboubakar Mounchili³, Denise Gravel-Tropper³, Patrick Quail⁴, Allison McGeer⁵, Andrea Moser^{6,7}, Madeleine Ashcroft⁸, Peter Daley^{9,10}, Katrina Piggott^{11,12}, Jerome Leis^{11,12}, Mark Morrissey¹

Abstract

Background: Antimicrobial resistance (AMR) is associated with significant human and financial costs, particularly among vulnerable populations like older adults living in long-term care homes (LTCHs). Urinary tract infection (UTI) is the leading indication for antibiotic use in this population, with some estimates suggesting that up to 70% of these prescriptions may be avoidable.

Objective: The purpose of this study is to develop and test novel behavioural science-informed antimicrobial stewardship (AMS) quality improvement strategies in Canadian LTCHs, which aim to decrease unnecessary testing and treatment for residents who lack the minimum clinical signs and symptoms of UTI.

Intervention: The quality improvement strategy is a two-pronged approach that includes 1) targeted education for essential care providers (family and friends of LTCH residents) about UTI and benefits of AMS, which strives to outline a positive role for this group in UTI management, and 2) monthly feedback to LTCH staff on their facility's urine culture ordering rates.

Outcomes: The protocol was piloted in a single LTCH; a process evaluation of the pilot implementation served to refine the research protocol, which is being implemented in eight LTCHs across Canada using an eight-month stepped wedge randomized cluster design.

Conclusion: This protocol represents a behavioural science-informed intervention to improve AMS across LTCHs. If successful, this model of care could be scalable across Canadian LTCHs, offering an inclusive approach that aims to empower clinicians, non-regulated healthcare staff, residents and their family and friends to improve health outcomes as antibiotic stewards.

Suggested citation: Good T, Cila J, Mosher R, Puka K, Reynolds S, Catt B, Mounchili A, Gravel-Tropper D, Quail P, McGeer A, Moser A, Ashcroft M, Daley P, Piggott KL, Leis JA, Morrissey M. Using behavioural science to improve antibiotic stewardship in Canadian long-term care homes: Protocol for a multi-center cluster randomized quality improvement study. *Can Commun Dis Rep* 2025;51(1):43–53. <https://doi.org/10.14745/ccdr.v51i01a06>

Keywords: antimicrobial resistance, antimicrobial stewardship, education, essential care provider, long-term-care home, audit and feedback, urinary tract infection, urine culture order

This work is licensed under a [Creative Commons Attribution 4.0 International License](#).



Affiliations

[See Appendix C](#)

*Correspondence:

tyler.good@phac-aspc.gc.ca



Introduction

The World Health Organization has identified antimicrobial resistance (AMR) as one of the top ten threats to global public health (1), with serious human and financial costs (2). Some Canadian estimates indicate that up to 50% of antibiotic prescriptions in outpatient settings (3), and nearly 25% in hospital settings (4), are avoidable. Residents of long-term care homes (LTCHs) are increasingly frail and particularly vulnerable to high rates of antibiotic use and antimicrobial-resistant infections (5,6), risk of adverse outcomes linked to avoidable antibiotic use (7) and relatively less developed antimicrobial stewardship (AMS) programs compared to other sectors (8). The leading indication for antibiotic use in LTCHs is urinary tract infections (UTI) (9), as it makes up over half of antibiotics prescribed in this sector (10), with up to 70.5% of these prescriptions considered clinically unnecessary (9). At the core of this challenge is the occurrence of asymptomatic bacteriuria, which is remarkably prevalent, being present in up to 50% of LTCH residents (5,11). Asymptomatic bacteriuria is the expected presence of bacteria in an appropriately collected urine specimen, in absence of clinical symptoms of UTI. Positive urine cultures that identify asymptomatic bacteriuria are frequently attributed to UTI for many non-specific presentations, which underscores the importance of limiting urine culture collection to situations where minimum clinical symptoms are present. An upstream focus on the judicious use of urine cultures is known to result in significant reductions in antibiotic use of asymptomatic bacteriuria (12,13) and may significantly improve AMS in LTCHs.

Evidence suggests that AMS interventions in LTCH can reduce antibiotic prescribing, especially for the treatment of UTI (14–16), including a recent meta-analysis showing a 14% overall reduction in antimicrobial use (8). Upstream interventions targeting urine culture, known as diagnostic stewardship interventions, may be most effective at reducing unnecessary antibiotic prescriptions for UTI (10,12,13,17–20). Importantly, a recent systematic review found AMS interventions did not increase risk of hospital admission or death, indicating that these programs did not lead to under-treatment of infection (21).

Behavioural science offers a useful lens for addressing antimicrobial resistance (22). Behavioural science frameworks have been used to understand the drivers and barriers affecting stewardship behaviours (23), as foundation for AMS interventions (24–28). In the current work, findings from an initial literature review (29) were synthesized with stakeholder interview results into a series of mapping exercises that narrowed from a systems, to behaviour, to cognitive map. In this way, we formalized our understanding of how prescribing decisions are influenced by the context of the individual resident, their caregivers, the clinical environment, the healthcare system and the surrounding culture. We then used a barrier prioritization exercise with a working group of experts to identify barriers for our quality improvement (QI) strategies to address. This

resulted in development of a two-pronged QI strategy for reducing diagnostic testing and antibiotic treatment of UTI when not clinically indicated. The first strategy consists of targeted education for essential care providers (ECPs; someone who provides important care for a resident and who is not on the medical team, e.g., family member or friend) to address ECP expectations for testing and treatment of UTI when not warranted. The second QI strategy consists of facility-level, monthly feedback about urine culture usage and reminders of guidelines, which will be given to LTCH staff to address the barrier of perceived risk of negative outcomes when choosing non-testing/treatment. Both QI strategies do not require explicit changes to work processes of LTCH staff, an important and advantageous consideration at a time when the Canadian healthcare sector faces human resource challenges.

The effectiveness of the QI strategies will be evaluated by assessing expected reductions in urine culture orders and antibiotic prescriptions for UTI. Whenever possible, we will also examine the proportion of urine cultures aligned with guidelines before and after intervention. A mixed-methods approach will evaluate the success of the study, with qualitative data helping contextualize quantitative findings.

The purpose of this study is to test novel behavioural AMS interventions in support of optimizing testing and treatment of UTI in LTCHs. The primary quantitative research questions are as follows: 1) What is the baseline usage of urine cultures in participating LTCHs?; and 2) Does implementation of the proposed QI strategies reduce the rates of a) urine cultures, b) antibiotic prescriptions for UTI and c) overall antibiotic prescriptions? Exploratory research questions will examine the baseline proportion of urine cultures aligned with guidelines and what risk factors are associated with collection of urine cultures when not aligned with guidelines. Qualitative data will also be collected to nuance quantitative findings.

Methods

Study overview

The study will be conducted in two stages. In the Pilot Stage, the protocol was implemented in a single LTCH for process evaluation (see **Appendix A: Protocol refinements**). The Trial Stage involves implementation in eight other LTCHs across Canada, with the main objective being an outcomes evaluation. The Trial Stage is designed as a stepped-wedge cluster randomized quality improvement study (**Table 1**) using a mixed-method approach. Quantitative data will evaluate the effectiveness of the protocol at reducing both testing and treatment for UTI, and qualitative data will contextualize the findings. Long-term care homes will be randomized to different starting times for the crossover from the control to intervention



Table 1: Overview of the stepped-wedge design

LTCH	Cluster	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6	Month 7	Month 8
a	1	C	C	T	I	I	I	I	I
b	1	C	C	T	I	I	I	I	I
c	2	C	C	C	T	I	I	I	I
d	2	C	C	C	T	I	I	I	I
e	2	C	C	C	T	I	I	I	I
f	3	C	C	C	C	T	I	I	I
g	4	C	C	C	C	C	T	I	I
h	4	C	C	C	C	C	T	I	I

Abbreviations: C, Control Phase (usual care is given); I, Intervention Phase (implementation of intervention); LTCH, long-term care home; T, Transition Phase (initiation of intervention)

phases, with staff and residents blinded to their allocation sequence. Here, we present the final protocol, including changes informed by Pilot Stage findings. For a complete list of refinements made to the protocol following the Pilot Stage, refer to Appendix A: Protocol refinements.

Sample characteristics

A purposive sampling strategy was used to recruit large (approximately 200 residents) LTCHs across Canada. To be eligible, LTCHs had to provide long-term (permanent placement) residential care with 24-hour monitoring and medical assistance. Sample size calculations using Hemming and Taljaard’s approach (30) indicated that eight LTCHs across four clusters, observed for a total of eight months, would be sufficient to detect a clinically meaningful 20% reduction in rate of urine culture ordering (6.5 to 5.2 urine cultures per 1,000 resident days) at greater than 80% power and 5% significance level. The effect size is in line with previous studies that observed greater than 25% reduction in urine culture ordering (31,32) and is more conservative than 25% reduction used in sample size calculations for a similarly designed trial (33).

Two limitations of this trial are its smaller sample size and the purposive sampling technique, which will not provide a representative sample of LTCHs across Canada. However, this is the first pilot study of a novel intervention, so the smaller more homogenous sample will provide initial evidence on the effectiveness of the strategies, which will allow for improvement of the processes and materials.

Pilot Stage

The Pilot Stage took place in a single LTCH from May to August 2023, starting with retrospective data collection (for the period February 2022 to January 2023), continuing with a transition phase where the QI strategies were brought online and concluding with a one-month intervention phase. The main output from the Pilot Stage was a process evaluation to gather exploratory and evaluative insights to validate study materials, check assumptions, identify gaps in the interventions and evaluate in-field processes. A series of semi-structured interviews with LTCH staff (n=3), a focus group with ECPs (n=2), voluntary online surveys (n=10) and direct observation of the materials

deployed in the home informed the process evaluation. In addition to these targeted sources of information input from the frontline workers of the Local Implementation Team was valuable to ground and validate our analytical interpretations in a deeper understanding of the local context of the home (34–36).

Fewer ECPs participated in the focus group than anticipated and this was likely at least partially due to the necessary timing of the pilot during the summer months, especially as the regular touchpoint of the resident family and friends council was on hiatus. However, even these few responses provided a valuable level of nuance regarding ECPs’ perceptions of the educational materials and of UTI treatment best practices that helped to identify areas for consideration and improvement for the stepped-wedge trial.

Retrospective data collection

Facility and demographic data will be collected along with proposed outcomes metrics for a retrospective one-year period to provide historical insight, contextualize these data with home demographics and serve as true baseline for comparison with intervention phase data. Participating LTCHs will be provided detailed data dictionaries and template data entry forms to ensure consistency.

Control Phase

The Control Phase will last between two and five months, depending on cluster number (Table 1). During the Control Phase, usual care will be given to the LTCH residents, and minimum and additional data elements (such as the number of urine cultures ordered and catheter use) will be collected on a monthly basis, as necessary, to answer both the primary and exploratory research questions. The complete list of variables is provided in **Appendix B: Outcome metrics**.

Transition Phase

During the one-month Transition Phase, the research team will liaise with each LTCH to coordinate education and delivery of the interventions. The goals of the Transition Phase are to 1) provide level-setting foundational AMS knowledge and practices to help standardize the intervention across participating LTCHs and 2) coordinate the implementation of the intervention. To further



ensure alignment, the research team will offer to connect the medical leadership of each LTCH with a physician member of the study working group for an optional peer-to-peer conversation about the guidelines and their experience with implementation within their practice.

During this phase the research team will deliver brief education sessions for LTCH staff (nurses, physicians, non-regulated healthcare staff, pharmacists) about the overprescribing of antibiotics, a reminder of when it is and is not appropriate to test for and treat UTI in older adults (37,38) and practices that can contribute to this problem. These sessions will be delivered in-person or by webinar at the discretion of the LTCHs. A recording will be made available for new staff and those unable to attend the synchronous sessions.

Intervention Phase

The Intervention Phase will consist of two primary strategies: 1) ECP education and 2) monthly feedback letters to LTCH staff about facility urine culture ordering.

Essential care providers education: Although educational components are common in AMS interventions within LTCHs (14,18,38–46), they typically target physicians and/or nurses. Fewer studies have provided education for ECPs (11), despite ECPs' influence on testing and treatment decisions (16,47–49). We designed these educational resources to increase understanding of AMS and the harms of unnecessary antimicrobial use among ECPs, and to outline a positive advocacy role for ECPs in UTI management.

Drawing on lessons learned from the Pilot Stage, taking a multi-modal approach to ECP education will help reach a broader audience among this diverse target population. Brief education sessions will be delivered in-person by a LTCH staff trained by the research team and asynchronously by leveraging digital communications and in-home communications (e.g., UTI best practice posters in common areas). In-person and live virtual sessions will be offered monthly, with exact frequency to reflect each LTCH's unique needs, and delivered within regularly occurring events (e.g., monthly LTCH town halls). Educational materials will also be distributed to ECPs through videos, posters, newsletters and physical handouts made available at the LTCH. We hypothesize that this intervention will reduce urine culture ordering and antibiotic prescribing by increasing ECPs' knowledge about AMS and, therefore, decreasing caregiver expectations for these tests and treatments when not clinically indicated.

Feedback letter: This strategy consists of monthly feedback given to LTCH staff (i.e., nurses, non-regulated healthcare staff, pharmacists, physicians) that shows the rate of urine cultures ordered by their facility in the past month relative to their previous data (retrospective, Control, Transition and previous

Intervention Phase when relevant). Audit and feedback on antibiotic prescription use have been embraced for use with physicians (50). Feedback to nurses and non-regulated healthcare staff, however, has not been used as an intervention strategy in LTCHs, yet these professionals play particularly important roles in LTCHs. They collaborate with physicians in making these decisions typically by assessing the resident and communicating their observations to the physician and, in some cases, collecting a urine sample before the physician has assessed the resident (49,51–53). Comparing recent with past performance acts as a self-comparison, which can motivate recipients by establishing personal norms (54) and has been effective in other contexts (55). Feedback will also indicate the proportion of urine cultures aligned with best practice guidelines (for LTCHs able to collect signs and symptoms data), which is a more specific measure of stewardship than overall ordering rate alone (56). We hypothesize that the feedback strategy will increase institutional awareness and reduce perceived risk of negative outcomes of urine culture avoidance, ultimately leading to a decrease in urine cultures and antibiotic prescriptions.

Feedback will be provided to all LTCH staff (nurses, non-regulated healthcare staff, pharmacists, physicians) starting after the first month of the Intervention Phase, for a total of two to five cycles of feedback depending on the cluster number. The LTCH implementation team will work with the research team to identify appropriate medium(s) for this feedback (e.g., central communications location on the floor, email, bulletin boards, regular staff meetings). The feedback letter will also include reminders regarding urine culture ordering decision guidelines (37,38) and links to additional resources.

Study measures

De-identified quantitative data will be collected monthly during the Control, Transition and Intervention Phases. Minimum data elements needed to answer the primary research questions include number of urine cultures ordered, antibiotic prescriptions for UTI, total antibiotic prescriptions and total days of residence. Additional data elements are necessary to answer the exploratory research questions and include signs and symptoms prompting urine culture orders, resident demographic characteristics, chronic conditions and functional status.

To contextualize the quantitative findings with the perspectives of the end users (LTCH staff and ECPs), we will additionally 1) conduct semi-structured interviews with 3–6 staff members from each LTCH after the Intervention Phase; 2) hold 2–3 focus groups with 4–6 ECPs each, within two months of the end of the intervention phase; and 3) collect qualitative data on perceptions and experience with the study through voluntary online questionnaires available to all LTCH staff and ECPs throughout the study. As with the Pilot Stage, qualitative data collection and validation will be supported by Local Implementation Teams.



Data analysis

A series of descriptive (continuous variables) and frequency analyses (categorical variables) will be conducted to get a global sense of the sample responses.

Analysis will be done at the level of the LTCH as an intention-to-treat analysis. To evaluate research question 1, rate of urine culture (per 1,000 resident days) will be calculated for the retrospective data period. To evaluate research question 2a, a generalized linear mixed-effects model will be used to assess whether or not the intervention has an effect on the rate of urine culture (per 1,000 resident days). The model will include categorical, fixed effects for phase (control/intervention) and for each month to account for secular trends, as well as a random effects for LTCH. Data from the Transition Phase will be excluded from these analyses as we do not consider these data to be clearly Control or Intervention Phase data. To evaluate research questions 2b and 2c, a similar model will be used with the outcome measures rate of antibiotic prescriptions for UTI and total antibiotic prescriptions per 1,000 resident days. Exploratory analyses will use a similar model to evaluate the potential effect of the intervention on rate of urine cultures not aligned with guidelines. Alignment with guidelines will be estimated by comparing the signs and symptoms prompting each urine culture to meet the modified Loeb minimum criteria for UTI for a catheterized or non-catheterized resident (37,38).

Thematic analysis will be guided by ethnographic methods and Normalization Process Theory. Taking an iterative approach that draws on Grounded Theory (35), open-ended codes will be applied alongside selected evaluative codes developed from a Normalization Process Theory perspective (57,58). Ethnographic data reduction techniques will be applied to surface focused insights to support the overarching research questions for the study (34,36,59).

Refinements to intervention based on Pilot Stage

A series of key observations drawn from the suite of qualitative methods employed were noted during the Pilot Stage: most staff who participated in interviews and ECPs who participated in the questionnaire and/or focus group viewed UTI guidelines as only relevant to residents without dementia, despite the guidelines' validation in LTCHs with residents with and without dementia (37,38). To address this challenge, two adjustments were made to the protocol: 1) the addition of an optional peer-to-peer conversation between the medical leadership of the LTCH and a physician member of the study's expert working group and 2) the revision of educational materials to highlight validation of guidelines in LTCHs and share experience in management of residents with dementia, including those that are non-communicative. For a full accounting of revisions in response to preliminary findings, see Appendix A.

Findings from the questionnaire, focus group and observations by staff interviewees and the Local Implementation Team indicated that the educational component of the intervention was generally appreciated by the ECPs, seeing it as relevant to their role as caregiver. However, it was observed across our qualitative data that ECPs constituted a heterogeneous group and scheduling was, at times, challenging. Therefore, we increased our flexibility to offer multimodal delivery of educational materials (i.e., poster, handout, in-person session, video).

Regarding the feedback letter, members of the Local Implementation Team and all interviewed staff (n=3) expressed uncertainty about the intended use and action. Some concerns regarding the peer-comparison were also raised, highlighting the challenge of inter-home comparisons. To address these challenges, the following changes to the protocol were made: 1) inclusion of an estimate of proportion of urine cultures aligned with guidelines to provide a more actionable metric, 2) shift from peer-comparison to self-comparison to emphasize continual self-improvement and 3) highlighting links to additional supports and resources.

Conclusion

This study will rigorously evaluate the impact of a behavioural science-informed intervention to improve AMS across LTCHs. If successful, this model of care could be scalable across Canadian LTCHs, offering an inclusive approach that aims to empower clinicians, non-regulated healthcare staff, residents and their family and friends to improve health outcomes as antibiotic stewards.

Authors' statement

TG — Conceptualization, methodology, writing—original draft, writing—review & editing, investigation, data curation & analysis, project administration
 JC — Methodology, writing—original draft, writing—review & editing
 RM — Methodology, writing—original draft, writing—review & editing, investigation, data curation & analysis, project administration
 KPuka — Methodology, writing—review & editing, data curation & analysis
 SR — Methodology, writing—review & editing, project administration
 BC — Methodology, writing—review & editing, project administration
 AMouchili — Methodology, writing—review & editing
 DG-T — Conceptualization, methodology, writing—review & editing
 PQ — Conceptualization, methodology, writing—review & editing
 AMcGeer — Methodology, writing—review & editing
 AMoser — Conceptualization, methodology, writing—review & editing
 MA — Conceptualization, methodology, writing—review & editing
 PD — Conceptualization, methodology, writing—review & editing



KPiggott — Conceptualization, methodology, writing–review & editing
 JL — Conceptualization, methodology, writing–review & editing
 MM — Conceptualization, methodology, writing–review & editing, investigation, project administration

Competing interests

Dr. Leis reports support from Choosing Wisely Canada for a leadership role in the Using Antibiotics Wisely campaign. Dr. Moser is a board member of the Canadian Society for Long-Term Care and Ontario Long Term Care Clinicians and is also in a contracted role as the Corporate Medical Director for the City of Toronto’s Senior Services and Long-Term Care Division and by the Institute for Safe Medication Practices. Madeleine Ashcroft sits on the Infection Prevention and Control Canada Board as Director of Standards and Guidelines. Dr. Piggott has a leadership role on Choosing Wisely Canada Geriatric Medicine.

ORCID numbers

Tyler Good — [0000-0002-4153-3917](https://orcid.org/0000-0002-4153-3917)
 Jorida Cila — [0000-0001-8741-0683](https://orcid.org/0000-0001-8741-0683)
 Rhiannon Mosher — [0000-0001-9230-2740](https://orcid.org/0000-0001-9230-2740)
 Klajdi Puka — [0000-0001-7763-988X](https://orcid.org/0000-0001-7763-988X)
 Patrick Quail — [0000-0002-9745-0993](https://orcid.org/0000-0002-9745-0993)
 Allison McGeer — [0000-0001-5647-6137](https://orcid.org/0000-0001-5647-6137)
 Andrea Moser — [0009-0001-5871-9785](https://orcid.org/0009-0001-5871-9785)
 Peter Daley — [0000-0001-7068-8056](https://orcid.org/0000-0001-7068-8056)
 Katrina Piggott — [0000-0001-7039-0436](https://orcid.org/0000-0001-7039-0436)
 Jerome Leis — [0000-0003-2250-4894](https://orcid.org/0000-0003-2250-4894)
 Mark Morrissey — [0000-0002-3300-162X](https://orcid.org/0000-0002-3300-162X)

Acknowledgments

No.

Funding

The Public Health Agency of Canada, through the Antimicrobial Resistance Task Force is the funder of this research. Compensation will be provided directly to each participating home.

References

1. EClinicalMedicine. Antimicrobial resistance: a top ten global public health threat. *EClinicalMedicine* 2021;41:101221. [DOI PubMed](#)
2. Public Health Agency of Canada. Canadian Antimicrobial Resistance Surveillance System Report—Update 2020. Ottawa, ON: PHAC; 2020. <https://www.canada.ca/en/public-health/services/publications/drugs-health-products/canadian-antimicrobial-resistance-surveillance-system-2020-report.html>
3. Saatchi A, Reid JN, Povitz M, Shariff SZ, Silverman M, Morris AM, Reyes RC, Patrick DM, Marra F. Appropriateness of outpatient antibiotic use in seniors across two Canadian provinces. *Antibiotics (Basel)* 2021;10(12):1484. [DOI PubMed](#)
4. Public Health Agency of Canada. Pan-Canadian Action Plan on Antimicrobial Resistance. Ottawa, ON: PHAC; 2023. <https://www.canada.ca/en/public-health/services/publications/drugs-health-products/pan-canadian-action-plan-antimicrobial-resistance.html>
5. Eze N, Cecchini M, Hashiguchi TC. Antimicrobial resistance in long-term care facilities. *OECD Health Working Papers*. No. 136. OECD 2022. [DOI](#)
6. van Buul LW, van der Steen JT, Veenhuizen RB, Achterberg WP, Schellevis FG, Essink RT, van Benthem BH, Natsch S, Hertogh CM. Antibiotic use and resistance in long term care facilities. *J Am Med Dir Assoc* 2012;13(6):568.e1–13. [DOI PubMed](#)
7. Daneman N, Bronskill SE, Gruneir A, Newman AM, Fischer HD, Rochon PA, Anderson GM, Bell CM. Variability in Antibiotic Use Across Nursing Homes and the Risk of Antibiotic-Related Adverse Outcomes for Individual Residents. *JAMA Intern Med* 2015;175(8):1331–9. [DOI PubMed](#)
8. Wu JH, Langford BJ, Daneman N, Friedrich JO, Garber G. Antimicrobial Stewardship Programs in Long-Term Care Settings: A Meta-Analysis and Systematic Review. *J Am Geriatr Soc* 2019;67(2):392–9. [DOI PubMed](#)
9. Penney C, Boyd SE, Mansfield A, Dalton J, O’Keefe J, Daley PK. Antimicrobial use and suitability in long-term care facilities: A retrospective cross-sectional study. *JAMMI* 2018;3(4):209–16. [DOI](#)
10. Pulia M, Kern M, Schwei RJ, Shah MN, Sampene E, Crnich CJ. Comparing appropriateness of antibiotics for nursing home residents by setting of prescription initiation: a cross-sectional analysis. *Antimicrob Resist Infect Control* 2018;7:74. [DOI PubMed](#)



11. Brown KA, Chambers A, MacFarlane S, Langford B, Leung V, Quirk J, Schwartz KL, Garber G. Reducing unnecessary urine culturing and antibiotic overprescribing in long-term care: a before-and-after analysis. *CMAJ Open* 2019;7(1):E174–81. [DOI PubMed](#)
12. Trautner BW, Grigoryan L, Petersen NJ, Hysong S, Cadena J, Patterson JE, Naik AD. Effectiveness of an Antimicrobial Stewardship Approach for Urinary Catheter-Associated Asymptomatic Bacteriuria. *JAMA Intern Med* 2015;175(7):1120–7. [DOI PubMed](#)
13. Smith MA, Puckrin R, Lam PW, Lamb MJ, Simor AE, Leis JA. Association of Increased Colony-Count Threshold for Urinary Pathogens in Hospitalized Patients With Antimicrobial Treatment. *JAMA Intern Med* 2019;179(7):990–2. [DOI PubMed](#)
14. Nace DA, Hanlon JT, Crnich CJ, Drinka PJ, Schweon SJ, Anderson G, Perera S. A Multifaceted Antimicrobial Stewardship Program for the Treatment of Uncomplicated Cystitis in Nursing Home Residents. *JAMA Intern Med* 2020;180(7):944–51. [DOI PubMed](#)
15. Rehan Z, Pratt C, Babb K, Filier B, Gilbert L, Wilson R, Daley P. Modified reporting of positive urine cultures to reduce treatment of asymptomatic bacteriuria in long-term care facilities: a randomized controlled trial. *JAC Antimicrob Resist* 2022;4(5):dlac109. [DOI PubMed](#)
16. Scales K, Zimmerman S, Reed D, Beeber AS, Kistler CE, Preisser JS, Weiner BJ, Ward K, Fann A, Sloane PD. Nurse and Medical Provider Perspectives on Antibiotic Stewardship in Nursing Homes. *J Am Geriatr Soc* 2017;65(1):165–71. [DOI PubMed](#)
17. Lohfeld L, Loeb M, Brazil K. Evidence-based clinical pathways to manage urinary tract infections in long-term care facilities: a qualitative case study describing administrator and nursing staff views. *J Am Med Dir Assoc* 2007;8(7):477–84. [DOI PubMed](#)
18. Pasay DK, Guirguis MS, Shkrobot RC, Slobodan JP, Wagg AS, Sadowski CA, Conly JM, Saxinger LM, Bresee LC. Antimicrobial stewardship in rural nursing homes: impact of interprofessional education and clinical decision tool implementation on urinary tract infection treatment in a cluster randomized trial. *Infect Control Hosp Epidemiol* 2019;40(4):432–7. [DOI PubMed](#)
19. Stagg A, Lutz H, Kirpalaney S, Matelski JJ, Kaufman A, Leis J, McCready J, Powis J. Impact of two-step urine culture ordering in the emergency department: a time series analysis. *BMJ Qual Saf* 2018;27(2):140–7. [DOI PubMed](#)
20. Vaughn VM, Gupta A, Petty LA, Malani AN, Osterholzer D, Patel PK, Younas M, Bernstein SJ, Burdick S, Ratz D, Szymczak JE, McLaughlin E, Czilok T, Basu T, Horowitz JK, Flanders SA, Gandhi TN. A Statewide Quality Initiative to Reduce Unnecessary Antibiotic Treatment of Asymptomatic Bacteriuria. *JAMA Intern Med* 2023;183(9):933–41. [DOI PubMed](#)
21. Crespo-Rivas JC, Guisado-Gil AB, Peñalva G, Rodríguez-Villodres Á, Martín-Gandul C, Pachón-Ibáñez ME, Lepe JA, Cisneros JM. Are antimicrobial stewardship interventions effective and safe in long-term care facilities? A systematic review and meta-analysis. *Clin Microbiol Infect* 2021;27(10):1431–8. [DOI PubMed](#)
22. Sirota M, Habersaat KB, Betsch C, Bonga DL, Borek A, Buckel A, Butler R, Byrne-Davis L, Caudell M, Charani E, Geiger M, Gross M, Hart J, Kostopoulou O, Krockow EM, Likki T, Lo Fo Wong D, Santana AP, Sievert ED, Theodoropoulou A, Thorpe A, Wanat M, Böhm R. We must harness the power of social and behavioural science against the growing pandemic of antimicrobial resistance. *Nat Hum Behav* 2023;8(1):11–3. [DOI PubMed](#)
23. Crayton E, Richardson M, Fuller C, Smith C, Liu S, Forbes G, Anderson N, Shallcross L, Michie S, Hayward A, Lorencatto F. Interventions to improve appropriate antibiotic prescribing in long-term care facilities: a systematic review. *BMC Geriatr* 2020;20(1):237. [DOI PubMed](#)
24. Chappell N, Gerard C, Gyani A, Hamblin R, Jansen RM, Lawrence A, Mackay J, Minko N, Roberts S, Shuker C, Te Karu L, White J. Using a randomised controlled trial to test the effectiveness of social norms feedback to reduce antibiotic prescribing without increasing inequities. *N Z Med J* 2021;134(1544):13–34. [PubMed](#)
25. Australian Government. Department of the Prime Minister and Cabinet. Nudge vs Superbugs: A behavioural economics trial to reduce the overprescribing of antibiotics. Canberra, AU: Australian Government; 2017. <https://behaviouraleconomics.pmc.gov.au/projects/nudge-vs-superbugs-behavioural-economics-trial-reduce-overprescribing-antibiotics>
26. Hallsworth M, Chadborn T, Sallis A, Sanders M, Berry D, Greaves F, Clements L, Davies SC. Provision of social norm feedback to high prescribers of antibiotics in general practice: a pragmatic national randomised controlled trial. *Lancet* 2016;387(10029):1743–52. [DOI PubMed](#)



27. Meeker D, Linder JA, Fox CR, Friedberg MW, Persell SD, Goldstein NJ, Knight TK, Hay JW, Doctor JN. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices a randomized clinical trial. *JAMA* 2016;315(6):562–70. [DOI PubMed](#)
28. Parzen-Johnson S, Kronforst KD, Shah RM, Whitmer GR, Scardina T, Chandarraju M, Patel SJ. Use of the Electronic Health Record to Optimize Antimicrobial Prescribing. *Clin Ther* 2021;43(10):1681–8. [DOI PubMed](#)
29. Vyas N, Good T, Cila J, Morrissey M, Tropper DG. Antibiotic prescribing and antimicrobial stewardship in long-term care facilities: past interventions and implementation challenges. *Can Commun Dis Rep* 2022;48(11/12):512–21. [DOI PubMed](#)
30. Hemming K, Taljaard M. Sample size calculations for stepped wedge and cluster randomised trials: a unified approach. *J Clin Epidemiol* 2016;69:137–46. [DOI PubMed](#)
31. Jump RL, Olds DM, Seifi N, Kyriotakis G, Jury LA, Peron EP, Hirsch AA, Drawz PE, Watts B, Bonomo RA, Donskey CJ. Effective antimicrobial stewardship in a long-term care facility through an infectious disease consultation service: keeping a LID on antibiotic use. *Infect Control Hosp Epidemiol* 2012;33(12):1185–92. [DOI PubMed](#)
32. Zabarsky TF, Sethi AK, Donskey CJ. Sustained reduction in inappropriate treatment of asymptomatic bacteriuria in a long-term care facility through an educational intervention. *Am J Infect Control* 2008;36(7):476–80. [DOI PubMed](#)
33. Jokanovic N, Haines T, Cheng AC, Holt KE, Hilmer SN, Jeon YH, Stewardson AJ, Stuart RL, Spelman T, Peel TN, Peleg AY; START Trial Group. Multicentre stepped-wedge cluster randomised controlled trial of an antimicrobial stewardship programme in residential aged care: Protocol for the START trial. *BMJ Open* 2021;11:e046142. <https://bmjopen.bmj.com/content/bmjopen/11/3/e046142.full.pdf>
34. Ladner, S. *Mixed methods: A short guide to mixed methods*. Sam Ladner; 2019.
35. Charmaz K. *Grounded Theory. Approaches to Qualitative Research: A Reader on Theory and Practice*. Oxford University Press 2004;496–521.
36. Sangaramoorthy T, Kroeger KA. *Rapid Ethnographic Assessments: A Practical Approach and Toolkit for Collaborative Community Research*. London: Routledge; 2020.
37. Loeb M, Bentley DW, Bradley S, Crossley K, Garibaldi R, Gantz N, McGeer A, Muder RR, Mylotte J, Nicolle LE, Nurse B, Paton S, Simor AE, Smith P, Strausbaugh L. Development of minimum criteria for the initiation of antibiotics in residents of long-term-care facilities: results of a consensus conference. *Infect Control Hosp Epidemiol* 2001;22(2):120–4. [DOI PubMed](#)
38. Loeb M, Brazil K, Lohfeld L, McGeer A, Simor A, Stevenson K, Zoutman D, Smith S, Liu X, Walter SD. Effect of a multifaceted intervention on number of antimicrobial prescriptions for suspected urinary tract infections in residents of nursing homes: cluster randomised controlled trial. *BMJ* 2005;331(7518):669. [DOI PubMed](#)
39. Cooper DL, Titler M, Struble L, Redman R. A multifaceted, evidence-based program to reduce inappropriate antibiotic treatment of suspected urinary tract infections. *Ann Longterm Care* 2017;25(2):36–43. <https://www.hmpgloballearningnetwork.com/site/altc/articles/multifaceted-evidence-based-program-reduce-inappropriate-antibiotic-treatment-suspected>
40. Fleet E, Gopal Rao G, Patel B, Cookson B, Charlett A, Bowman C, Davey P. Impact of implementation of a novel antimicrobial stewardship tool on antibiotic use in nursing homes: a prospective cluster randomized control pilot study. *J Antimicrob Chemother* 2014;69(8):2265–73. [DOI PubMed](#)
41. McMaughan DK, Nwaiwu O, Zhao H, Frentzel E, Mehr D, Imanpour S, Garfinkel S, Phillips CD. Impact of a decision-making aid for suspected urinary tract infections on antibiotic overuse in nursing homes. *BMC Geriatr* 2016 Apr;16:81. [DOI PubMed](#)
42. Monette J, Miller MA, Monette M, Laurier C, Boivin JF, Sourial N, Le Cruguel JP, Vandal A, Cotton-Montpetit M. Effect of an educational intervention on optimizing antibiotic prescribing in long-term care facilities. *J Am Geriatr Soc* 2007;55(8):1231–5. [DOI PubMed](#)
43. Naughton BJ, Mylotte JM, Ramadan F, Karuza J, Priore RL. Antibiotic use, hospital admissions, and mortality before and after implementing guidelines for nursing home-acquired pneumonia. *J Am Geriatr Soc* 2001;49(8):1020–4. [DOI PubMed](#)
44. Pettersson E, Vernby A, Mölsted S, Lundborg CS. Can a multifaceted educational intervention targeting both nurses and physicians change the prescribing of antibiotics to nursing home residents? A cluster randomized controlled trial. *J Antimicrob Chemother* 2011;66(11):2659–66. [DOI PubMed](#)



45. van Buul LW, van der Steen JT, Doncker SM, Achterberg WP, Schellevis FG, Veenhuizen RB, Hertogh CM. Factors influencing antibiotic prescribing in long-term care facilities: a qualitative in-depth study. *BMC Geriatr* 2014;14:136. [DOI PubMed](#)
46. Zimmerman S, Sloane PD, Bertrand R, Olsho LE, Beeber A, Kistler C, Hadden L, Edwards A, Weber DJ, Mitchell CM. Successfully reducing antibiotic prescribing in nursing homes. *J Am Geriatr Soc* 2014;62(5):907–12. [DOI PubMed](#)
47. Kistler CE, Zimmerman S, Scales K, Ward K, Weber D, Reed D, McClester M, Sloane PD. The Antibiotic Prescribing Pathway for Presumed Urinary Tract Infections in Nursing Home Residents. *J Am Geriatr Soc* 2017;65(8):1719–25. <https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.14857>
48. Laur C, Sribaskaran T, Simeoni M, Desveaux L, Daneman N, Mulhall C, Lam J, Ivers NM. Improving antibiotic initiation and duration prescribing among nursing home physicians using an audit and feedback intervention: a theory-informed qualitative analysis. *BMJ Open Qual* 2021;10(1):e001088. [DOI PubMed](#)
49. Schweizer AK, Hughes CM, Macauley DC, O'Neill C. Managing urinary tract infections in nursing homes: a qualitative assessment. *Pharm World Sci* 2005;27(3):159–65. [DOI PubMed](#)
50. Schwartz KL, Xu AX, Alderson S, Bjerrum L, Brehaut J, Brown BC, Bucher HC, De Sutter A, Francis N, Grimshaw J, Gunnarsson R, Hoye S, Ivers N, Lecky DM, Lindbæk M, Linder JA, Little P, Michalsen BO, O'Connor D, Pulcini C, Sundvall PD, Lundgren PT, Verbakel JY, Verheij TJ. Best practice guidance for antibiotic audit and feedback interventions in primary care: a modified Delphi study from the Joint Programming Initiative on Antimicrobial resistance: Primary Care Antibiotic Audit and Feedback Network (JPIAMR-PAAN). *Antimicrob Resist Infect Control* 2023;12(1):72. [DOI PubMed](#)
51. Ramly E, Tong M, Bondar S, Ford JH 2nd, Nace DA, Crnich CJ. Workflow Barriers and Strategies to Reduce Antibiotic Overuse in Nursing Homes. *J Am Geriatr Soc* 2020;68(10):2222–31. [DOI PubMed](#)
52. Russell J, Gallen D. Influencing factors on antibiotic prescribing in nursing homes. *Prim Health Care Res Dev* 2003;4(1):69–75. [DOI](#)
53. Fleming A, Bradley C, Cullinan S, Byrne S. Antibiotic prescribing in long-term care facilities: a meta-synthesis of qualitative research. *Drugs Aging* 2015;32(4):295–303. [DOI PubMed](#)
54. Proman M, Brunswicker S. Affordances Of Eco-Feedback Design in Home Energy Context. American Conference on Information Systems. 2017. <https://aisel.aisnet.org/amcis2017/GreenIS/Presentations/7/>
55. Otaki Y, Honda H, Ueda K. Historical Self-Comparison of Water Consumption as a Water Demand Management Tool. *Water* 2019;11(4):844. [DOI](#)
56. Chung GW, Wu JE, Yeo CL, Chan D, Hsu LY. Antimicrobial stewardship: a review of prospective audit and feedback systems and an objective evaluation of outcomes. *Virulence* 2013;4(2):151–7. [DOI PubMed](#)
57. Kousgaard MB, Olesen JA, Arnold SH. Implementing an intervention to reduce use of antibiotics for suspected urinary tract infection in nursing homes - a qualitative study of barriers and enablers based on Normalization Process Theory. *BMC Geriatr* 2022;22(1):265. [DOI PubMed](#)
58. May C, Finch T. Implementation, embedding, and integration: An outline of Normalization Process Theory. *Sociology* 2009;43(3):535–54. [DOI](#)
59. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. *BMC Med Res Methodol* 2013;13:117. [DOI PubMed](#)



Appendices

Appendix A: Protocol refinements

The following table summarizes changes made to the protocol following the Pilot Stage. The protocol described in the paper reflects these changes.

Change	Change made	Description
1	Addition of an optional peer-to-peer conversation between physician member of the study expert working group and medical leadership at each home at the beginning of the Transition Phase	A goal of our Transition Phase is level-setting (getting everyone on the same page) about foundational AMS knowledge and practices. To facilitate this, we meet with the implementation team at each LTCH and review current practices and alignment with guidelines. To strengthen this, the protocol now includes an optional peer-to-peer conversation between a physician member of the working group and the medical leadership at each LTCH (i.e., Medical Director, Physician Chief). The intention is for these conversations to cover the evidence supporting the guidelines and the experiences the working group member had in implementing them in their practice.
2	Explicit inclusion of clinical pharmacists and personal support workers	The protocol now calls for clinical pharmacists employed by the home and non-regulated healthcare staff (sometimes referred to as personal support workers or nursing assistants) to attend the introductory education session provided during the Transition Phase, along with nursing staff and physicians. Previously these groups were not explicitly named in our protocol, despite being likely to interact with study materials present in staff areas (e.g., a monthly feedback report at the nursing station). This change appropriately includes them as important members of the clinical team that a portion of the responsibility for AMS.
3	Increased flexibility in delivery of staff introductory education session	The duration of the introductory education session was reduced to 5–10 minutes and the protocol calls for it to be presented in-person, by webinar or via recorded video at the discretion of the LTCH. This increased flexibility is intended to allow for the adaption to the unique circumstances and procedures of staff training at each LTCH. The session is now provided to nurses, physicians, clinical pharmacists and non-regulated healthcare staff (personal support workers, nursing assistants, etc.), as per change 2.
4	Narrowing of prospective data collection	The protocol now includes collection of signs and symptoms prompting all urine culture orders during the Control, Transition and Intervention Phases. This allows an estimation of the proportion of cultures that are aligned with guidelines. A measure of alignment with guidelines will allow for a more precise measure of AMS compared to rate of urine culture alone. Alignment with guidelines will be used as an exploratory evaluation of the success of the trial (pre-post comparison) as well as a component of the feedback report. To balance the additional workload to LTCHs collecting this data, the protocol also limits the previously required monthly facility-level demographic data from all residents of the LTCH to only those who received a urine culture. The previous monthly facility-level demographics provided little additional value to the cross-sectional demographic data collected with the retrospective data. If some LTCHs are unable to provide signs and symptoms data, we will 1) report this finding, which will highlight an important knowledge gap, 2) remain adequately powered to evaluate the study using rate of urine culture order and 3) antibiotic prescription for UTI as previously planned.
5	Updates to feedback letter content	The protocol now calls for the feedback letter to provide a self-comparison of LTCH urine culture order rate over time, as well as an estimate of the proportion of urine culture orders that were aligned with guidelines. Previously, the protocol called for a peer-comparison of urine culture order rate between the LTCHs included in the Trial Stage, as well as comparison with historical data. The change avoids limitations of inter-home comparisons and allows for a focus on self-comparison in the spirit of continual improvement.
6	Increased opportunity for qualitative engagement with staff	The protocol calls for a minimum of three, but opportunity for six semi-structured interviews at each LTCH. This is a change from the previous protocol which required three interviews, with no opportunity for more. The protocol also includes a voluntary online questionnaire available to LTCH staff. This mirrors the questionnaire provided to ECPs, asking about LTCH staff's experience with our study and suggestions for improvements. Together, these changes provide opportunity to supplement qualitative findings from a previously small number of interviews, only if there is interest and capacity at each LTCH. The online questionnaire provides a mechanism for all LTCH staff to share feedback, if they choose to do so.

Abbreviations: AMS, antimicrobial stewardship; ECP, essential care provider; LTCH, long-term care home; UTI, urinary tract infection



Appendix B: Outcome metrics

The intervention study will be collecting data on the following key outcomes:

1. Outcomes related to urine culture orders
 - a. Baseline prevalence of urine cultures for diagnosis of urinary tract infections (UTIs)
 - b. Effect of intervention on decreasing rate of urine culture orders
 - c. Effect of intervention on decreasing rate of urine culture orders aligned with guidelines
2. Outcomes related to antibiotic use
 - a. Baseline usage of antibiotics
 - b. Effect of intervention on reducing incidence of antibiotic prescriptions written for suspected UTIs
 - c. Effect of intervention on reducing duration of written urinary antibiotic prescriptions
 - d. Effect of intervention on reducing incidence of total antibiotic prescriptions
 - e. Effect of intervention on duration of total antibiotic prescriptions
3. Outcomes related to essential care provider (ECP) education
 - a. Long-term care home (LTCH) staff perceptions on whether ECP education reduced pressure from ECPs to collect urine cultures for testing when not clinically indicated
 - b. LTCH staff perceptions on whether ECP education reduced pressure from ECPs for antibiotic treatment of UTIs when not clinically indicated
4. Outcomes related to feedback letter
 - a. LTCH staff perceptions on whether the feedback letter reduced their perceived risk of negative outcomes when not ordering diagnostic testing or treatment for UTIs when not clinically indicated

In addition to the above, we will also be collecting data on additional outcomes to test some exploratory research questions (e.g., result of urine culture; antibiotic dosage, duration and route of administration; catheter use; ethnicity; sex; age; chronic conditions).

Appendix C: Affiliations

¹ Data, Surveillance and Foresight Branch, Public Health Agency of Canada, Ottawa, ON

² Impact & Innovation Unit, Privy Council Office, Ottawa, ON

³ Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, ON

⁴ Department of Family Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB

⁵ Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON

⁶ Department of Family and Community Medicine, University of Toronto, Toronto, ON

⁷ City of Toronto Senior Services and Long-Term Care Division, Toronto, ON

⁸ Trillium Health Partners, Toronto, ON

⁹ Newfoundland and Labrador Health Services, Memorial University of Newfoundland, St. John's, NL

¹⁰ Memorial University of Newfoundland, St. John's, NL

¹¹ Sunnybrook Health Sciences Centre, Toronto, ON

¹² Department of Medicine and Centre for Quality Improvement and Patient Safety, Temerty Faculty of Medicine, University of Toronto, Toronto, ON